Cost-Effectiveness Analysis of a Once-Daily Single-Inhaler Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease (COPD) Using the FULFIL Trial: A Spanish Perspective.
Melanie SchroederNicole BenjaminLaura AtienzaChandroday BiswasAlan A MartinJohn D WhalenJosé Luis Izquierdo AlonsoJuan Antonio Riesco MirandaJuan José Soler-CataluñaAlicia HuertaAfisi S IsmailaPublished in: International journal of chronic obstructive pulmonary disease (2020)
At the accepted Spanish ICER threshold of €30,000, FF/UMEC/VI represents a cost-effective treatment option vs BUD/FOR in patients with symptomatic COPD at risk of exacerbations.